A literature review of changes in phase ii drug-metabolizing enzyme and drug transporter expression during pregnancy
C Gong, LN Bertagnolli, DW Boulton, P Coppola - Pharmaceutics, 2023 - mdpi.com
The purpose of this literature review is to comprehensively summarize changes in the
expression of phase II drug-metabolizing enzymes and drug transporters in both the …
expression of phase II drug-metabolizing enzymes and drug transporters in both the …
Raltegravir in HIV-1–Infected pregnant women: pharmacokinetics, safety, and efficacy
MI Blonk, APH Colbers… - Clinical infectious …, 2015 - academic.oup.com
Background. The use of raltegravir in human immunodeficiency virus (HIV)–infected
pregnant women is important in the prevention of mother-to-child HIV transmission …
pregnant women is important in the prevention of mother-to-child HIV transmission …
Pharmacokinetics of HIV-integrase inhibitors during pregnancy: mechanisms, clinical implications and knowledge gaps
R van der Galiën, R Ter Heine, R Greupink… - Clinical …, 2019 - Springer
Prevention of mother-to-child transmission of HIV and optimal maternal treatment are the
most important goals of antiretroviral therapy in pregnant women with HIV. These goals may …
most important goals of antiretroviral therapy in pregnant women with HIV. These goals may …
Integrase inhibitors in late pregnancy and rapid HIV viral load reduction
L Rahangdale, J Cates, JN Potter, ML Badell… - American journal of …, 2016 - Elsevier
Background Minimizing time to HIV viral suppression is critical in pregnancy. Integrase
strand transfer inhibitors (INSTIs), like raltegravir, are known to rapidly suppress plasma HIV …
strand transfer inhibitors (INSTIs), like raltegravir, are known to rapidly suppress plasma HIV …
[图书][B] Pharmacology Research And Textbook 2: HIV-1 Integrase Inhibitors, Coenzyme Q10, and Ferroptosis
Page 1 Pharmacology Research And Textbook 2 Chapter1: HIV-1 Integrase Inhibitors and
Neurodevelopment Chapter2: Coenzyme Q10 Chapter3: Ferroptosis Author in Chief …
Neurodevelopment Chapter2: Coenzyme Q10 Chapter3: Ferroptosis Author in Chief …
Pharmacokinetics and placental transfer of elvitegravir, dolutegravir, and other antiretrovirals during pregnancy
BH Rimawi, E Johnson, A Rajakumar… - Antimicrobial agents …, 2017 - Am Soc Microbiol
The integrase inhibitors elvitegravir (EVG) and dolutegravir (DTG) rapidly decrease the
plasma HIV-1 viral load, a key factor in the prevention of maternal-to-fetal transmission of …
plasma HIV-1 viral load, a key factor in the prevention of maternal-to-fetal transmission of …
Prediction of maternal and fetal pharmacokinetics of dolutegravir and raltegravir using physiologically based pharmacokinetic modeling
XI Liu, JD Momper, NY Rakhmanina, DJ Green… - Clinical …, 2020 - Springer
Background Predicting drug pharmacokinetics in pregnant women including placental drug
transfer remains challenging. This study aimed to develop and evaluate maternal–fetal …
transfer remains challenging. This study aimed to develop and evaluate maternal–fetal …
HPLC-MS/MS method for the simultaneous quantification of dolutegravir, elvitegravir, rilpivirine, darunavir, ritonavir, raltegravir and raltegravir-β-d-glucuronide in …
Y Zheng, R Aboura, S Boujaafar, G Lui, D Hirt… - … of Pharmaceutical and …, 2020 - Elsevier
Therapeutic drug monitoring (TDM) is essential in the optimization of antiretroviral (ARV)
treatments. In this work, we describe a new method for the simultaneous quantification of six …
treatments. In this work, we describe a new method for the simultaneous quantification of six …
Effects of initiating raltegravir-based versus efavirenz-based antiretroviral regimens during pregnancy on weight changes and perinatal outcomes: NICHD P1081
Background: Integrase inhibitors have been associated with excess gestational weight gain
that may lead to adverse pregnancy outcomes (APOs). This post hoc analysis of NICHD …
that may lead to adverse pregnancy outcomes (APOs). This post hoc analysis of NICHD …
Physiologically based pharmacokinetic modeling framework to predict neonatal pharmacokinetics of transplacentally acquired emtricitabine, dolutegravir, and …
XI Liu, JD Momper, NY Rakhmanina, DJ Green… - Clinical …, 2021 - Springer
Abstract Background and Objective Little is understood about neonatal pharmacokinetics
immediately after delivery and during the first days of life following intrauterine exposure to …
immediately after delivery and during the first days of life following intrauterine exposure to …